ストックスクリーナーアプリを入手
4.24
2.42%
0.10
Maxcyte Inc (MXCT) 最新ニュース
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,111 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Shareholder Voting Rights Due to BlackRock Holdings - TipRanks
BlackRock Adjusts Stake in MaxCyte, Influencing Voting Rights - TipRanks
MaxCyte (LON:MXCT) Shares Up 3.4%Here's Why - MarketBeat
MaxCyte (LON:MXCT) Shares Up 3.4% – Here’s Why - Defense World
Fmr LLC Lowers Stake in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
MaxCyte cuts 15% of global workforce, boosts core revenue guidance - MSN
MaxCyte, Inc. Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte Announces Change in Major Shareholdings - TipRanks
Getting In Cheap On MaxCyte, Inc. (LON:MXCT) Might Be Difficult - Simply Wall St
MaxCyte Streamlines Workforce and Boosts Revenue Outlook - MSN
MaxCyte Shares Surge On Boost to Revenue-Growth Outlook - MarketWatch
MaxCyte ups core revenue guidance for 2024 as eyes 2025 cost savings - Marketscreener.com
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance Provide Update - citybiz
MaxCyte Inc slashes workforce by 15%, ups revenue forecast - TradingPedia
MaxCyte upgrades revenue guidance after operational review - ShareCast
Intech Investment Management LLC Purchases New Shares in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance - The Manila Times
MaxCyte cuts 15% of global workforce, boosts core revenue guidance (NASDAQ:MXCT) - Seeking Alpha
MaxCyte Restructures with 15% Job Cuts, Boosts 2024 Revenue Growth Outlook to 8% - StockTitan
ArrowMark Colorado Holdings LLC Purchases 169,250 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
MaxCyte Expands Stock Capital Amid Cell Therapy Growth - TipRanks
MaxCyte Sees Shift in BlackRock’s Shareholding - MSN
MaxCyte’s Voting Rights Shift with BlackRock Acquisition - MSN
MaxCyte, Inc. (NASDAQ:MXCT) Shares Purchased by Mudita Advisors LLP - MarketBeat
Electroporation Enables Efficient Antibody Discovery By Mammalian Display - BioProcess Online
Accelerate Antibody Development And Production - BioProcess Online
This MaxCyte Insider Increased Their Holding In The Last Year - Yahoo Finance
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
MaxCyte stock touches 52-week low at $3.23 amid market challenges - Investing.com Canada
Will MaxCyte's Q2 Results Surpass Market Expectations? - RTTNews
CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc - GuruFocus.com
MaxCyte Celebrates 25 Years - Baystreet.ca
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - The Manila Times
MaxCyte Marks 25 Years of Innovation with Groundbreaking Cell Therapy Breakthrough | MXCT Stock News - StockTitan
Pinterest Inc (PINS-N) QuotePress Release - The Globe and Mail
MaxCyte stock touches 52-week low at $3.27 amid market shifts - Investing.com Canada
MaxCyte stock touches 52-week low at $3.27 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
FY2024 Earnings Estimate for MaxCyte Issued By William Blair - MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Call Transcript - MSN
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Investors ignore increasing losses at MaxCyte (LON:MXCT) as stock jumps 10% this past week - Simply Wall St
MaxCyte Files Quarterly Report, Highlights Financial Progress - TipRanks
MaxCyte’s Revenue Grows and Strategic Moves Unveiled - TipRanks
MaxCyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Constellation Energy Corp (CEG-Q) QuotePress Release - The Globe and Mail
MaxCyte Director Sells Shares Amid Active Trading - TipRanks
1.54%
大文字化:
|
ボリューム (24 時間):